8 Weeks
10 mg Vial- VialsBPC-157 + TB-500 Blend (Wolverine Stack) mg vials
- 6
- U-100 Syringesone sterile syringe per dose
- 62
- BAC Water30 mL multi-dose vials
- 2
- Alcohol Padsvial stopper + skin prep
- 118
56 total doses over 8 weeks
Body Protection Compound 157 + Thymosin Beta-4 Fragment Blend
A 1:1 co-lyophilized blend of BPC-157 and TB-500 sold as a single vial (5 mg/5 mg or 10 mg/10 mg). Nicknamed the 'Wolverine stack,' it pairs BPC-157's localized angiogenic and gut-protective effects with TB-500's systemic actin-regulating, cell-migration effects so one injection covers both repair pathways.
BPC-157 + TB-500 Blend (Wolverine Stack) Reference VialMulti-Peptide Vial Composition
Select your vial strength to update all reference concentrations, dosage tables, and syringe draws on this page.
Arithmetic summary: Reconstituting a 10 mg BPC-157 + TB-500 Blend (Wolverine Stack) vial with 2 mL of bacteriostatic water yields 5 mg/mL. Every 10 units (0.10 mL) on a U-100 insulin syringe delivers 500 mcg.
BPC-157 + TB-500 Blend (Wolverine Stack) · 10 mg VialArithmetic summary: Reconstituting a 20 mg BPC-157 + TB-500 Blend (Wolverine Stack) vial with 2 mL of bacteriostatic water yields 10 mg/mL. Every 10 units (0.10 mL) on a U-100 insulin syringe delivers 1000 mcg.
BPC-157 + TB-500 Blend (Wolverine Stack) · 20 mg VialSelect a row to preview the draw on the syringe. Values are reference figures from the literature, not medical advice.
| Phase | Dose | mL | Units | Doses/Vial |
|---|---|---|---|---|
| BeginnerOnce daily · Weeks 1–2 | 500 mcg (250 BPC / 250 TB) | 0.10 | 10 | 20 |
| StandardOnce daily · Weeks 3–4 | 750 mcg (375 BPC / 375 TB) | 0.15 | 15 | 13 |
| TargetOnce daily · Weeks 5–8+ | 1 mg (500 BPC / 500 TB) | 0.20 | 20 | 10 |
| Phase | Dose | mL | Units | Doses/Vial |
|---|---|---|---|---|
| BeginnerOnce daily · Weeks 1–2 | 500 mcg (250 BPC / 250 TB) | 0.05 | 5 | 40 |
| StandardOnce daily · Weeks 3–4 | 750 mcg (375 BPC / 375 TB) | 0.08 | 7.5 | 26 |
| TargetOnce daily · Weeks 5–8+ | 1 mg (500 BPC / 500 TB) | 0.10 | 10 | 20 |
U-100 syringe drawn to 10 units (0.10 mL), 500 mcg (250 BPC / 250 TB).
Dose exceeds this syringe's capacity. Choose a larger syringe or reduce the diluent volume.
Click any dosing tier row above to preview that exact draw on the U-100 syringe scale.
Four steps, in order. Work on a clean surface with washed hands and swab every vial top with alcohol first.
Step 01Draw 2 mL of bacteriostatic water (0.9% benzyl alcohol) into a sterile syringe. Use bacteriostatic, not plain sterile water, so the multi-dose vial stays preserved between draws.
Step 02Pierce the stopper and angle the needle at 45° so the water runs slowly down the inside glass wall. Never spray directly onto the lyophilized puck: the jet foams the solution and can denature fragile peptide chains.
Step 03Roll the vial gently between your fingers or swirl in a slow circle until the liquid is 100% clear with no undissolved particles. Shaking shears peptide bonds and traps air bubbles; if it clouds, let it rest in the fridge for 15 minutes.
Step 04Write the reconstitution date and concentration on the vial. Refrigerate upright at 2–8 °C (36–46 °F), protected from light, and use within 28–30 days. Do not freeze the reconstituted liquid.
Convert a lyophilized peptide vial amount and bacteriostatic water volume into a reconstitution concentration, then translate your protocol dose and schedule into exact U-100 syringe units and multi-week vial supplies.
Enter the peptide amount in the vial and the volume of bacteriostatic or sterile water you plan to add.
Concentration
How much peptide each mL of solution contains after mixing.
5 mg/mL
Enter the dose from your protocol, select your dosing schedule, and pick the insulin syringe you are using.
100-unit (1 mL): marks every 2 units. Standard barrel for draws up to 100 units.
Draw to
Pull plunger seal to line 5
Volume
0.05 mL
Delivers 250 mcg
Doses per vial
20
Lasts 20 days (Once daily)
4-Week Schedule Supply
2 vials
28 doses · 2.0 mL BAC water
| Duration | Total Peptide | Vials Required | U-100 Syringes | BAC Water |
|---|
For educational and research calculations only. Always confirm calculations independently before use.
Plan vials, U-100 insulin syringes, bacteriostatic water, and sterile alcohol prep pads by protocol duration.

BPC-157 + TB-500 Blend (Wolverine Stack) Vials (10 mg each):
U-100 Insulin Syringes & Alcohol Pads:
56 total doses over 8 weeks
84 total doses over 12 weeks
112 total doses over 16 weeks

BPC-157 + TB-500 Blend (Wolverine Stack) Vials (20 mg each):
U-100 Insulin Syringes & Alcohol Pads:
56 total doses over 8 weeks
84 total doses over 12 weeks
112 total doses over 16 weeks
Synergistic Protocols
Common research and clinical combinations pairing BPC-157 + TB-500 Blend (Wolverine Stack) with complementary pathways.
Accelerates tendon, ligament, muscle, and joint recovery by pairing localized angiogenesis (BPC-157) with systemic actin upregulation (TB-500).
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| BPC-157 | 250–500 mcg daily (10–20 U on 5mg/2mL) | Once or split AM/PM SubQ |
| TB-500 (Thymosin Beta-4) | 2.0–2.5 mg twice weekly (or 350–500 mcg daily) | SubQ abdominal or near injury |
Stacking Note: Can be drawn into the same insulin syringe immediately prior to injection or purchased as a pre-mixed 10mg/10mg blend vial.
Combines high-dose copper peptide (50 mg GHK-Cu) with 10 mg BPC-157 and 10 mg TB-500 to remodel collagen, elastin, skin density, and connective tissue while minimizing copper injection sting.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| GHK-Cu (Copper Peptide) | 1.75–2.5 mg per daily draw | Once daily SubQ (3 mL BAC in 70 mg vial) |
| BPC-157 | 350–500 mcg per daily draw | Co-administered in blend |
| TB-500 | 350–500 mcg per daily draw | Co-administered in blend |
Stacking Note: Standard 70 mg GLOW vial reconstituted with 3.0 mL BAC water: drawing 7–10 units delivers ~1.6–2.3 mg GHK-Cu + 330–460 mcg each of BPC-157 and TB-500.
Adds 10 mg KPV (alpha-MSH tripeptide) to the GLOW formula to downregulate NF-kB/TNF-alpha systemic and gastrointestinal inflammation.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| GHK-Cu + BPC-157 + TB-500 | 50 mg / 10 mg / 10 mg base | Once daily SubQ (3 mL BAC in 80 mg vial) |
| KPV Tripeptide | 350–500 mcg per daily draw | Co-administered in 80 mg KLOW vial |
Stacking Note: Ideal for protocols targeting simultaneous gut mucosal repair, autoimmune calm, and dermal/tendon remodeling.
Rotate sites with every injection so no single area is used twice in a row. Swab with alcohol and let it dry for 10 seconds before injecting.

Zone 01
Abdomen
≥ 2 in away from navel
Zone 02
Outer Thigh
Middle third, anterior-lateral
Zone 03
Upper Arm
Posterior / outer tricep pad
90° · 4–8 mm (31 G) short needle
Standard U-100 insulin syringe: pinch a light fold and insert straight in at 90°.
45° · 12.7 mm (1/2 in) needle
Longer needle or leaner area: pinch a 1-inch fold and enter at 45° into fat.
Aseptic Injection Checklist
• Use a brand-new sterile U-100 syringe for every draw (never reuse needles).
• Swab both the vial rubber stopper and injection site with 70% isopropyl alcohol and let dry.
• Rotate clockwise around the abdomen or alternate left/right thigh to prevent lipohypertrophy.
Lyophilized Powder (Unmixed)
Freezer −20 °C Long-Term · Fridge Short-Term
Unmixed freeze-dried vials stay stable for months in the refrigerator and 1–2+ years at −20 °C (0 °F) in the dark. Let the vial warm to room temperature before opening.
Reconstituted Liquid (Mixed)
Refrigerate 2–8 °C (36–46 °F) · Use Within 30 Days
Keep refrigerated and out of light once mixed with bacteriostatic water. Never freeze reconstituted liquid — ice crystals shear the dissolved peptide chains.
Pharmacology & Evidence
How It Works
BPC-157 promotes angiogenesis via VEGFR2 and the FAK-paxillin pathway and modulates nitric oxide signaling at the injury site, while TB-500 (thymosin beta-4 active fragment) sequesters G-actin to drive cell migration, reduces inflammatory cytokines, and promotes new blood vessel formation systemically. Combining the two targets local tissue remodeling and whole-body recovery in the same dose.
subcutaneous
500mcg-1mg · Daily
4-8 weeks
subcutaneous (maintenance)
500mcg · 3-5x weekly
Ongoing as needed
Research use only. Not medical advice.
Independent animal studies show each peptide accelerates tendon, muscle, and skin healing; combination data in humans remains anecdotal
Tβ4 increased endothelial cell migration and vessel sprouting in vitro and in rodent models
Research compound; not FDA-approved. Neither component is approved for human use in the United States, and BPC-157 is on the FDA Category 2 bulk-substance list restricting compounding.
Clinical Profile
Provider Directory
Sold by research peptide vendors as a pre-mixed lyophilized vial. Confirm the COA lists BOTH peptides at the stated mass; some vendors label the combined mass (10 mg) without specifying the ratio.
Free Guide
New studies, regulatory changes and sourcing notes on the peptides you follow. One email a week, no spam.
Free. No spam. Unsubscribe anytime. From GLP1Search.
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides